Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Website: tyra.bio




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.7% (LTM)

Entry Point: Share price is 327.3% higher than minimum and 2.4% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $9.8 mln (-1.265% of cap.)

Key Financials (Download financials)

Ticker: TYRA
Share price, USD:  (0.0%)30.17
year average price 14.52  


year start price 12.67 2025-02-08

min close price 7.06 2025-04-08

max close price 30.91 2026-01-22

current price 30.17 2026-02-07
Common stocks: 41 883 904

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 1 264
Net Debt ($m): -301
EV (Enterprise Value): 963
Price to Book: 4.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-02-11prnewswire.com

Tyra Biosciences to Present at Upcoming Investor Conferences

2025-01-22prnewswire.com

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

2025-01-10prnewswire.com

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

2024-11-07prnewswire.com

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

2024-10-28prnewswire.com

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

2024-10-21seekingalpha.com

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

2024-10-18benzinga.com

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

2024-10-11prnewswire.com

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

2024-09-11accesswire.com

Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation

2024-09-10prnewswire.com

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-14 2024-11-07 2024-08-07 2024-05-09 2023-11-07 2023-08-10 2023-05-04 2022-11-03
acceptedDate 2025-11-05 16:14:36 2025-08-14 16:17:47 2025-03-27 16:29:29 2024-11-07 16:13:07 2024-08-07 16:10:15 2024-05-09 16:12:29 2024-03-19 16:09:27 2023-11-07 16:16:24 2023-08-10 16:27:15 2023-05-04 16:16:08 2023-03-22 16:16:02 2022-11-03 16:34:30 2022-03-03 16:31:21 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 126 000 122 000 0 82 000 86 000 0 0 0 0 47 000
grossProfit 0 0 0 0 -126 000 -122 000 0 -82 000 -86 000 0 0 0 0 -47 000
grossProfitRatio 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 25M 24M 80M 23M 18M 17M 63M 19M 12M 10M 43M 11M 21M 7M
generalAndAdministrativeExpenses 7M 7M 24M 6M 6M 5M 17M 5M 4M 4M 16M 3M 6M 2M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 7M 7M 24M 6M 6M 5M 17M 5M 4M 4M 16M 3M 6M 2M
otherExpenses 0 0 0 0 0 0 0 -5000 -21 000 -1000 0 0 0 -23 000
operatingExpenses 33M 31M 104M 29M 23M 22M 80M 24M 16M 14M 59M 14M 26M 9M
costAndExpenses 33M 31M 104M 29M 24M 22M 80M 24M 16M 14M 59M 14M 26M 9M
interestIncome 0 3M 18M 5M 5M 4M 11M 3M 3M 2M 4M 1M 13 000 0
interestExpense 0 0 0 0 0 0 0 0 0 -2M 0 1M 0 1000
depreciationAndAmortization 131 000 140 000 519 000 127 000 126 000 122 000 357 000 82 000 86 000 83 000 296 000 82 000 140 000 47 000
ebitda -30M -31M -104M -28M -23M -22M -80M -24M -16M -14M -59M -14M -26M -9M
ebitdaratio 0 0 0 0 0 0 0 0 0
operatingIncome -33M -31M -104M -29M -24M -22M -80M -24M -16M -14M -59M -14M -26M -9M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 3M 3M 18M 5M 5M 4M 11M -5000 -21 000 2M 4M 1M -6000 -39 000
incomeBeforeTax -30M -28M -86M -24M -19M -18M -69M -21M -13M -12M -55M -13M -26M -9M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 78 724 0 -3M -3M -2M 0 -1M 0 0
netIncome -30M -28M -86M -24M -19M -18M -69M -21M -13M -9M -55M -11M -26M -9M
netIncomeRatio 0 0 0 0 0 0 0 0 0
eps -0.5 -0.47 -1.51 -0.41 -0.32 -0.35 -1.62 -0.49 -0.31 -0.22 -1.23 -0.27 -0.63 -0.22
epsdiluted -0.5 -0.47 -0.41 -0.32 -0.35 -0.49 -0.31 -0.22 -0.27
weightedAverageShsOut 60M 60M 57M 59M 59M 52M 43M 43M 43M 42M 42M 42M 41M 43M
weightedAverageShsOutDil 60M 60M 57M 59M 59M 52M 43M 43M 43M 42M 42M 42M 41M 43M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2024-03-19 2023-03-22 2022-03-03 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 18M 11M 4M 13 000 -999
ebit -104M -80M -59M -26M -9M
nonOperatingIncomeExcludingInterest 0 0 0 0 38 000
netIncomeFromContinuingOperations -86M -69M -55M -26M -9M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -86M -69M -55M -26M -9M
epsDiluted -1.51 -1.62 -1.23 -0.63 -0.22

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-14 2024-11-07 2024-08-07 2024-05-09 2023-11-07 2023-08-10 2023-05-04 2022-11-03
acceptedDate 2025-11-05 16:14:36 2025-08-14 16:17:47 2025-03-27 16:29:29 2024-11-07 16:13:07 2024-08-07 16:10:15 2024-05-09 16:12:29 2024-03-19 16:09:27 2023-11-07 16:16:24 2023-08-10 16:27:15 2023-05-04 16:16:08 2023-03-22 16:16:02 2022-11-03 16:34:30 2022-03-03 16:31:21 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 62M 98M 92M 104M 99M 254M 58M 216M 232M 242M 251M 263M 302M 15M
shortTermInvestments 213M 198M 249M 256M 274M 128M 145M 0 0 0 0 0 0 0
cashAndShortTermInvestments 275M 296M 341M 360M 374M 382M 203M 216M 232M 242M 251M 263M 302M 15M
netReceivables 2M 2M 2M 0 0 2M 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 4M 4M 4M 5M 8M 7M 8M 9M 8M 5M 6M 4M 0 0
totalCurrentAssets 281M 302M 347M 366M 379M 391M 212M 225M 241M 242M 257M 267M 304M 15M
propertyPlantEquipmentNet 7M 7M 8M 8M 8M 8M 8M 7M 7M 3M 4M 4M 2M 466 000
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 1 000 000 0 0 0 1 000 000 1 000 000 0 1 000 000 1 000 000 0 0 0 0 243 000
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 13M 12M 8M 7M 5M 5M 6M 5M 866 000 5M 5M 5M 555 000 21 000
totalNonCurrentAssets 21M 19M 16M 15M 14M 14M 14M 14M 9M 8M 9M 9M 3M 730 000
otherAssets 0 0 0 0 0 1 0 0 0 -351M 0 0 0 0
totalAssets 302M 321M 364M 381M 392M 405M 226M 238M 250M -101M 266M 276M 307M 16M
accountPayables 2M 2M 590 000 1M 2M 3M 5M 2M 1M 1M 1M 3M 599 000 664 000
shortTermDebt 456 000 441 000 0 0 766 000 370 000 0 148 000 144 000 144 000 0 127 000 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 -383 000 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 13M 11M 14M 11M 8M 5M 5M 8M 4M 834 000 0 3M 0 278 000
totalCurrentLiabilities 16M 14M 15M 12M 10M 9M 15M 10M 5M 2M 6M 5M 4M 2M
longTermDebt 5M 6M 0 6M 6M 6M 0 6M 6M 2M 0 3M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 3000 11 000 20 000 29 000 46 000 77 000 108 000 139 000 169 000 -134 000 367 000 28M
totalNonCurrentLiabilities 5M 6M 6M 6M 6M 6M 6M 6M 6M 3M 3M 3M 1M 28M
otherLiabilities 0 0 0 0 0 0 0 0 0 -3M 0 0 0 0
capitalLeaseObligations 5M 6M 6M 6M 6M 6M 6M 6M 6M 3M 3M 3M 1M 142 000
totalLiabilities 21M 19M 20M 18M 16M 15M 22M 16M 11M 2M 8M 8M 5M 30M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 5000 5000 5000 5000 5000 5000 4000 4000 4000 4000 4000 4000 4000 0
retainedEarnings -337M -308M -251M -226M -202M -183M -165M -142M -121M -108M -96M -83M -40M -14M
accumulatedOtherComprehensiveIncomeLoss 442 000 436 000 770 000 2M -184 000 -6000 381 000 0 0 0 0 0 0 0
othertotalStockholdersEquity 617M 609M 586M 578M 573M 364M 359M -4000 351M
totalStockholdersEquity 281M 302M 343M 362M 376M 390M 204M 222M 239M -108M 258M 268M 302M -14M
totalEquity 281M 302M 343M 362M 376M 390M 204M 222M 239M -108M 258M 268M 302M -14M
totalLiabilitiesAndStockholdersEquity 302M 321M 381M 392M 405M 238M 250M -101M 276M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 302M 321M 364M 381M 392M 405M 226M 238M 250M -101M 266M 276M 307M 16M
totalInvestments 214M 198M 249M 256M 275M 129M 145M 1 000 000 1 000 000 0 0 0 0 243 000
totalDebt 6M 6M 6M 6M 6M 6M 6M 6M 6M 3M 3M 3M 1M 142 000
netDebt -56M -92M -86M -98M -93M -248M -52M -210M -226M -239M -249M -261M -301M -15M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2024-03-19 2023-03-22 2022-03-03 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 2M 0 0 0 0
prepaids 0 0 0 2M 57 000
totalPayables 590 000 5M 1M 599 000 664 000
otherPayables 0 0 0 0 0
accruedExpenses 0 5M 4M 3M 774 000
capitalLeaseObligationsCurrent 412 000 280 000 140 000 202 000 142 000
capitalLeaseObligationsNonCurrent 6M 6M 2M 981 000 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 594M 369M 354M 342M 439 000
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA TYRA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-14 2024-11-07 2024-08-07 2024-05-09 2023-11-07 2023-08-10 2023-05-04 2022-11-03
acceptedDate 2025-11-05 16:14:36 2025-08-14 16:17:47 2025-03-27 16:29:29 2024-11-07 16:13:07 2024-08-07 16:10:15 2024-05-09 16:12:29 2024-03-19 16:09:27 2023-11-07 16:16:24 2023-08-10 16:27:15 2023-05-04 16:16:08 2023-03-22 16:16:02 2022-11-03 16:34:30 2022-03-03 16:31:21 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -30M -28M -86M -24M -19M -18M -69M -21M -13M -12M -55M -13M -26M -9M
depreciationAndAmortization 131 000 140 000 519 000 127 000 126 000 122 000 353 000 82 000 86 000 83 000 296 000 82 000 140 000 47 000
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 8M 6M 23M 8M 4M 4M 0 4M 3M 2M 11M 1M 3M 439 000
changeInWorkingCapital 199 000 -1M -729 000 1M 6M -7M 6M -453 000 1M -483 000 -6M -805 000 -481 000 1M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 0 0 0 0 0 -7M 0 0 0 -2M 0 48 000 1M 1M
otherWorkingCapital 199 000 -1M -729 000 1M 6M -7M 6M -453 000 1M 2M -6M -853 000 -2M 51 000
otherNonCashItems -419 000 -708 000 -6M -3M 3M 3M 12M 1000 3000 0 3000 1000 3000 17 000
netCashProvidedByOperatingActivities -22M -24M -70M -18M -10M -22M -50M -17M -10M -10M -50M -12M -24M -8M
investmentsInPropertyPlantAndEquipment -39 000 -31 000 -664 000 -52 000 -470 000 -136 000 -770 000 -83 000 -43 000 -41 000 -559 000 -48 000 -661 000 -312 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 16 000 0
purchasesOfInvestments -65M -20M -264M -36M -177M -12M -144M 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 50M 41M 166M 58M 33M 30M 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 -1 -144 521 18 209 0 0 0 0
netCashUsedForInvestingActivites -15M 21M 22M -145M 18M -83 000 -43 000 -41 000 -48 000
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 647 000 583 000 -199M 0 200M 467 000 370 000 376 000 364 000
commonStockRepurchased 0 0 -420 000 420 000 -251 000 -169 000 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 743 000 373 000 200 315 467 0 0 0
netCashUsedProvidedByFinancingActivities 647 000 583 000 743 000 373 000 200M 467 000 370 000 376 000 364 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 -757 000 0 0 0
netChangeInCash -37M -2M 34M 5M -155M 196M -193M -17M -9M -10M -51M -12M 287M 15M
cashAtEndOfPeriod 62M 99M 93M 105M 99M 254M 58M 217M 233M 243M 251M 264M 302M 15M
cashAtBeginningOfPeriod 98M 102M 59M 99M 254M 58M 251M 233M 243M 252M 302M 276M 15M 108 000
operatingCashFlow -22M -24M -70M -18M -10M -22M -50M -17M -10M -10M -50M -12M -24M -8M
capitalExpenditure -39 000 -31 000 -664 000 -52 000 -470 000 -136 000 -770 000 -83 000 -43 000 -41 000 -559 000 -48 000 -661 000 -312 000
freeCashFlow -22M -24M -70M -18M -11M -22M -51M -17M -10M -10M -51M -12M -24M -8M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-27 2024-03-19 2023-03-22 2022-03-03 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 16 0
netCashProvidedByInvestingActivities -98M -145M -559 000 -645 000 -312 000
netDebtIssuance 0 0 0 -9000 -17 000
longTermNetDebtIssuance 0 0 0 -9000 -17 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 200M 2M 632 000 311M 23M
netCommonStockIssuance 200M 2M 632 000 181M 0
commonStockIssuance 200M 2M 632 000 181M 0
netPreferredStockIssuance 0 0 0 130M 23M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 3M 0 0 514 000 140 000
netCashProvidedByFinancingActivities 202M 2M 632 000 311M 23M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 1000

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2025-11-05 16:14 ET
Tyra Biosciences, Inc. reported for 2025 q3
SEC form 8
2025-11-05 16:08 ET
Tyra Biosciences, Inc. reported for 2025 q3
SEC form 8
2025-11-05 16:08 ET
Tyra Biosciences, Inc. published news for 2025 q3
SEC form 10
2025-08-14 20:17 ET
Tyra Biosciences, Inc. reported for 2025 q2
SEC form 8
2025-08-14 20:11 ET
Tyra Biosciences, Inc. reported for 2025 q2
SEC form 8
2025-08-14 20:11 ET
Tyra Biosciences, Inc. published news for 2025 q2
SEC form 10
2025-05-08 20:10 ET
Tyra Biosciences, Inc. reported for 2025 q1
SEC form 8
2025-05-08 20:06 ET
Tyra Biosciences, Inc. reported for 2025 q1
SEC form 8
2025-05-08 20:06 ET
Tyra Biosciences, Inc. published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Tyra Biosciences, Inc. reported for 2025 q1
SEC form 10
2025-03-27 16:29 ET
Tyra Biosciences, Inc. reported for 2024 q4
SEC form 8
2025-03-27 16:08 ET
Tyra Biosciences, Inc. published news for 2024 q4
SEC form 8
2025-03-27 16:08 ET
Tyra Biosciences, Inc. reported for 2024 q4
SEC form 10
2025-03-27 00:00 ET
Tyra Biosciences, Inc. reported for 2024 q4
SEC form 10
2024-11-07 16:13 ET
Tyra Biosciences, Inc. reported for 2024 q3
SEC form 8
2024-11-07 16:05 ET
Tyra Biosciences, Inc. published news for 2024 q3
SEC form 8
2024-11-07 16:05 ET
Tyra Biosciences, Inc. reported for 2024 q3
SEC form 10
2024-08-07 16:10 ET
Tyra Biosciences, Inc. published news for 2024 q2
SEC form 8
2024-08-07 16:05 ET
Tyra Biosciences, Inc. reported for 2024 q2
SEC form 8
2024-08-07 16:05 ET
Tyra Biosciences, Inc. published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Tyra Biosciences, Inc. published news for 2024 q2
SEC form 8
2024-05-09 00:00 ET
Tyra Biosciences, Inc. published news for 2024 q1
SEC form 10
2024-05-09 00:00 ET
Tyra Biosciences, Inc. reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Tyra Biosciences, Inc. reported for 2024 q1
SEC form 10
2024-03-19 16:09 ET
Tyra Biosciences, Inc. reported for 2023 q4
SEC form 8
2024-03-19 16:05 ET
Tyra Biosciences, Inc. reported for 2023 q4
SEC form 8
2024-03-19 16:05 ET
Tyra Biosciences, Inc. published news for 2023 q4
SEC form 10
2024-03-19 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q4
SEC form 10
2023-11-07 16:16 ET
Tyra Biosciences, Inc. reported for 2023 q3
SEC form 8
2023-11-07 16:07 ET
Tyra Biosciences, Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q3
SEC form 10
2023-08-10 16:27 ET
Tyra Biosciences, Inc. published news for 2023 q2
SEC form 6
2023-08-10 16:21 ET
Tyra Biosciences, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Tyra Biosciences, Inc. published news for 2023 q2
SEC form 8
2023-05-04 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Tyra Biosciences, Inc. reported for 2023 q1
SEC form 10
2023-03-22 16:16 ET
Tyra Biosciences, Inc. reported for 2022 q4
SEC form 6
2023-03-22 16:05 ET
Tyra Biosciences, Inc. reported for 2022 q4
SEC form 10
2023-03-22 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q4
SEC form 8
2023-03-22 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q4
SEC form 6
2023-03-01 07:30 ET
Tyra Biosciences, Inc. published news for 2022 q4
SEC form 6
2022-11-29 08:06 ET
Tyra Biosciences, Inc. published news for 2022 q3
SEC form 10
2022-11-03 16:34 ET
Tyra Biosciences, Inc. reported for 2022 q3
SEC form 6
2022-11-03 16:16 ET
Tyra Biosciences, Inc. reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q3
SEC form 6
2022-10-03 16:43 ET
Tyra Biosciences, Inc. published news for 2022 q3
SEC form 10
2022-08-04 16:35 ET
Tyra Biosciences, Inc. reported for 2022 q2
SEC form 6
2022-08-04 16:23 ET
Tyra Biosciences, Inc. reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q2
SEC form 6
2022-06-14 16:01 ET
Tyra Biosciences, Inc. published news for 2022 q1
SEC form 10
2022-05-05 16:32 ET
Tyra Biosciences, Inc. reported for 2022 q1
SEC form 6
2022-05-05 16:17 ET
Tyra Biosciences, Inc. reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Tyra Biosciences, Inc. reported for 2022 q1
SEC form 6
2022-04-28 16:07 ET
Tyra Biosciences, Inc. published news for 2022 q1
SEC form 10
2022-03-03 16:31 ET
Tyra Biosciences, Inc. published news for 2021 q4
SEC form 6
2022-03-03 16:16 ET
Tyra Biosciences, Inc. published news for 2021 q4
SEC form 8
2022-03-03 00:00 ET
Tyra Biosciences, Inc. published news for 2021 q4
SEC form 10
2022-03-03 00:00 ET
Tyra Biosciences, Inc. published news for 2021 q4
SEC form 10
2021-11-03 16:31 ET
Tyra Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-11-03 16:16 ET
Tyra Biosciences, Inc. published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Tyra Biosciences, Inc. published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Tyra Biosciences, Inc. published news for 2021 q3
SEC form 6
2021-09-17 16:01 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:21 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:21 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:20 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:19 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:19 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:18 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:17 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:17 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:17 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:15 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:15 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:14 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:13 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:12 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 21:11 ET
Tyra Biosciences, Inc. published news for 2021 q2
SEC form 6
2021-09-14 18:45 ET
Tyra Biosciences, Inc. published news for 2021 q2